Home > Market > Market Stats >  Dr. Lal Pathlabs

Dr. Lal Pathlabs

Sector: Healthcare Facilities
Powered by
2420.95 +30.30 (1.27%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 2371.25
Today’s High 2430.85
52 Week Low 1805.1
52 Week High 3943.95

Key Metrics

  • Market Cap (In Cr) 20029.04
  • Beta 0.65
  • Div. Yield (%) 0.5
  • P/B 13.27
  • TTM P/E 65.83
  • Peg Ratio 7.52
  • Sector P/E 45.25
  • D/E -
  • Open Price 2409.9
  • Prev Close 2390.65
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    -8.74%
  • 3 Months
    9.06%
  • 6 Month
    -13.01%
  • YTD
    -36.75%
  • 1 Year
    -35.75%
Risk Meter
  • 43% Low risk
  • 43% Moderate risk
  • 43% Balanced Risk
  • 43% High risk
  • 43% Extreme risk
Recos
20 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 3
  • Sell
  • 5
  • Hold
  • 3
  • Buy
  • 4
  • Strong Buy
  • 5

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 2087.41
  • Selling/ General/ Admin Expenses Total
  • 962.59
  • Depreciation/ Amortization
  • 108.11
  • Other Operating Expenses Total
  • 37.81
  • Total Operating Expense
  • 1632.88
  • Operating Income
  • 454.53
  • Net Income Before Taxes
  • 474.98
  • Net Income
  • 344.83
  • Diluted Normalized EPS
  • 41.63
  • Period
  • 2021
  • Total Revenue
  • 1581.27
  • Selling/ General/ Admin Expenses Total
  • 699.12
  • Depreciation/ Amortization
  • 77.2
  • Other Operating Expenses Total
  • 29.81
  • Total Operating Expense
  • 1222.01
  • Operating Income
  • 359.25
  • Net Income Before Taxes
  • 394.41
  • Net Income
  • 291.62
  • Diluted Normalized EPS
  • 35.26
  • Period
  • 2020
  • Total Revenue
  • 1330.36
  • Selling/ General/ Admin Expenses Total
  • 643.15
  • Depreciation/ Amortization
  • 72.81
  • Other Operating Expenses Total
  • 28.18
  • Total Operating Expense
  • 1059.59
  • Operating Income
  • 270.77
  • Net Income Before Taxes
  • 310.5
  • Net Income
  • 225.94
  • Diluted Normalized EPS
  • 27.36
  • Period
  • 2019
  • Total Revenue
  • 1203.42
  • Selling/ General/ Admin Expenses Total
  • 603.66
  • Depreciation/ Amortization
  • 38.22
  • Other Operating Expenses Total
  • 28.01
  • Total Operating Expense
  • 947.98
  • Operating Income
  • 255.44
  • Net Income Before Taxes
  • 300.55
  • Net Income
  • 199.18
  • Diluted Normalized EPS
  • 24.14
  • Period
  • 2018
  • Total Revenue
  • 1056.92
  • Selling/ General/ Admin Expenses Total
  • 527.48
  • Depreciation/ Amortization
  • 33.06
  • Other Operating Expenses Total
  • 24
  • Total Operating Expense
  • 825.89
  • Operating Income
  • 231.03
  • Net Income Before Taxes
  • 261.32
  • Net Income
  • 170.77
  • Diluted Normalized EPS
  • 20.83
  • Period
  • 2017
  • Total Revenue
  • 912.38
  • Selling/ General/ Admin Expenses Total
  • 443.84
  • Depreciation/ Amortization
  • 27.54
  • Other Operating Expenses Total
  • 20.07
  • Total Operating Expense
  • 702.1
  • Operating Income
  • 210.28
  • Net Income Before Taxes
  • 236.82
  • Net Income
  • 154.59
  • Diluted Normalized EPS
  • 18.97
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day2569.09
  • 10 Day2509.56
  • 20 Day2470.22
  • 50 Day2420.79
  • 100 Day2254.62
  • 300 Day2615.42

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 28-Jul-22
  • Quarterly Results & Interim Dividend
  • 17-May-22
  • Audited Results & Final Dividend
  • 10-Feb-22
  • Quarterly Results
  • 26-Oct-21
  • Quarterly Results
  • 30-Jul-21
  • Quarterly Results & Interim Dividend
  • 21-May-21
  • Audited Results & Final Dividend
  • 29-Jan-21
  • Quarterly Results & 2nd Interim Dividend

Company Profile

ABOUT Dr. Lal Pathlabs

  • Industry Healthcare Facilities
  • ISIN INE600L01024
  • BSE Code 539524
  • NSE Code LALPATHLAB

Dr. Lal PathLabs Limited is engaged in providing diagnostic and related healthcare tests and services. The Company is also engaged in running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and other pathological and radiological investigations. The Company offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, Dr. Lal PathLabs Nepal Private Limited, Dr. Lal PathLabs Bangladesh Pvt. Ltd. and Dr. Lal Ventures Private Limited.

MANAGEMENT

  • Arvind Lal Executive Chairman of the Board
  • Bharath Uppiliappan Chief Executive Officer
  • Ved Goel Chief Financial Officer
  • Rajat Kalra Compliance Officer, Company Secretary and Legal Head
  • Om Manchanda Managing Director, Executive Director
  • Vandana Lal Executive Director

Company Summary

DR. LAL PATHLABS SUMMARY

Dr. Lal Pathlabs is trading 1.27% upper at Rs 2420.95 as compared to its last closing price. Dr. Lal Pathlabs has been trading in the price range of 2430.85 & 2371.25. Dr. Lal Pathlabs has given -36.75% in this year & -8.74% in the last 5 days.

 

Dr. Lal Pathlabs has TTM P/E ratio 65.83 as compared to the sector P/E of 45.25. There are 20 analysts who have initiated coverage on Dr. Lal Pathlabs. There are 5 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 5 analysts have given the stock a sell rating.

 

The company posted a net profit of 57.7 Crores in its last quarter.

 

Listed peers of Dr. Lal Pathlabs include Max Healthcare Institute (-0.6%), Fortis Healthcare (2.17%), Dr. Lal Pathlabs (1.27%) etc.

FAQs about Dr. Lal Pathlabs

Dr. Lal Pathlabs is trading at 2420.95 as on 4 Oct, 2022 3:29:00 PM. This is 1.27% upper as compared to its previous closing price of 2390.65
The market capitalization of Dr. Lal Pathlabs is 20029.04 Cr as on 4 Oct, 2022 3:29:00 PM.
The average broker rating on Dr. Lal Pathlabs is Hold. The breakup of analyst rating is given below -
  • 3 analysts have given a strong sell rating
  • 5 analysts have given a sell rating
  • 3 analysts have given a hold rating
  • 4 analysts have given a buy rating
  • 5 analysts have given a strong buy rating
The 52 wk high for Dr. Lal Pathlabs is 3943.95 whereas the 52 wk low is 1805.1
Dr. Lal Pathlabs can be analyzed on the following key metrics -
  • TTM P/E: 65.83
  • Sector P/E: 45.25
  • Dividend Yield: 0.5%
  • D/E ratio: -
Dr. Lal Pathlabs reported a net profit of 344.83 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout